Focal neuromyotonia associated with a C9ORF72 expansion mutation

2020 ◽  
Vol 62 (4) ◽  
Author(s):  
Francesco Fortunato ◽  
Giuseppe Bonapace ◽  
Rosa Gullace ◽  
Monica Gagliardi ◽  
Rita Nisticò ◽  
...  
2018 ◽  
Vol 77 (8) ◽  
pp. 703-709 ◽  
Author(s):  
Oscar Ramos-Campoy ◽  
Rainiero Ávila-Polo ◽  
Oriol Grau-Rivera ◽  
Anna Antonell ◽  
Jordi Clarimón ◽  
...  

2019 ◽  
Vol 132 (5) ◽  
pp. jcs224303 ◽  
Author(s):  
Ana Bajc Česnik ◽  
Simona Darovic ◽  
Sonja Prpar Mihevc ◽  
Maja Štalekar ◽  
Mirjana Malnar ◽  
...  

2017 ◽  
Vol 13 (7S_Part_7) ◽  
pp. P337-P337
Author(s):  
Gorana Mandic Stojmenovic ◽  
Elka Stefanova ◽  
Valerija Dobricic ◽  
Ivana Novakovic ◽  
Tanja Stojkovic ◽  
...  

2012 ◽  
Vol 21 (1) ◽  
pp. 102-108 ◽  
Author(s):  
Bradley N Smith ◽  
Stephen Newhouse ◽  
Aleksey Shatunov ◽  
Caroline Vance ◽  
Simon Topp ◽  
...  

2016 ◽  
Vol 62 (2) ◽  
pp. 321-324 ◽  
Author(s):  
Huei-Hsin Chiang ◽  
Charlotte Forsell ◽  
Anna-Karin Lindström ◽  
Lena Lilius ◽  
Håkan Thonberg ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 601
Author(s):  
Keith Mayl ◽  
Christopher E. Shaw ◽  
Youn-Bok Lee

A hexanucleotide repeat expansion mutation in the first intron of C9orf72 is the most common known genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Since the discovery in 2011, numerous pathogenic mechanisms, including both loss and gain of function, have been proposed. The body of work overall suggests that toxic gain of function arising from bidirectionally transcribed repeat RNA is likely to be the primary driver of disease. In this review, we outline the key pathogenic mechanisms that have been proposed to date and discuss some of the novel therapeutic approaches currently in development.


2014 ◽  
Vol 261 (10) ◽  
pp. 1917-1921 ◽  
Author(s):  
Vladimir S. Kostić ◽  
Valerija Dobričić ◽  
Iva Stanković ◽  
Vesna Ralić ◽  
Elka Stefanova

Sign in / Sign up

Export Citation Format

Share Document